Sato-Asahara et al. [22] observed that serum IL-6 and monocyte IL-6 expression levels in T2D patients tended to decrease due to in vivo treatment with DPP-4 inhibitors. The gene discussed is IL6; the disease is type 2 diabetes mellitus.